ArticleiScience2026
Comparative analysis of breast cancer burden in China, India, and the United States.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer burden varies dramatically across countries at different stages of economic and epidemiological transition. This study assessed the burden, trends, and risk factors of female breast cancer in China, India, and the United States (1990-2023) using GBD 2023 data. Significant epidemiological heterogeneity was observed. India experienced the fastest rising burden, with its age-standardized incidence rate more than doubling. China showed a distinct pattern of rising incidence but declining mortality, while the United States demonstrated consistent declines across all burden indicators. Decomposition analysis revealed the increase in China was primarily driven by demographic factors, whereas India faced both demographic and adverse epidemiological changes. The United States achieved reductions through epidemiological improvements offsetting demographic pressures. Leading risk factors were high red meat intake (China), high fasting plasma glucose (India), and high body-mass index (the United States) Projections to 2050 indicate diverging trajectories, underscoring the need for tailored, country-specific prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.